Director, Clinical Pharmacology

Director, Clinical Pharmacology

You will join an innovative and passionate clinical development team at Recursion dedicated to improving the lives of patients suffering from devastating diseases. You will lead the innovative clinical pharmacology and pharmacometrics strategy and execution for a portfolio of rare disease and oncology clinical programs.

• Develop the clinical pharmacology and pharmacometric strategies to accelerate and support the overall product development plan.
• Design clinical studies and provide pharmacology input on all clinical study designs, from Phase 1‑3 and dedicated Phase 1 clinical pharmacology studies.
• Author review relevant clinical pharmacology sections for regulatory documents, including Investigator's Brochures (IB), INDs, NDAs and other regulatory submissions, and act as the clinical pharmacology expert during interactions with health authorities.
• Interface with cross‑functional teams and work closely with clinical study teams, translational teams (DMPK, Translational Modeling and Toxicology), preclinical teams and due diligence teams to ensure clinical pharmacology‑related considerations are addressed.
• Solve drug development questions/problems by overseeing and/or performing modeling and simulation with various tools to expedite decision making.

You will join the Development Sciences team within Recursion comprising clinical pharmacology, pharmacometrics, translational modeling and clinical biomarkers. The Development Sciences group sits within Recursion’s Clinical Development organization. Team members get to sit on both Discovery and Development projects and work in a seamless end‑to‑end environment. The team collaborates closely with clinical development functions (clinical science, clinical operations, regulatory affairs, biostatistics, etc.)

as well as discovery functions (DMPK, Biology, Chemistry and Translational Biomarkers).

• Ph.D. in Pharmaceutical Sciences, Pharmacokinetics or related discipline, M.D. with a Clinical Pharmacology expertise, or a Pharm.
  
  D. with a Clinical Pharmacology fellowship, with 5‑9+ years of experience in biotech/pharmaceutical drug development.
• Demonstrated success leading all clinical pharmacology related aspects of drug development.
• Ability to work closely with internal and external stakeholders to manage PK, PK‑PD, and PK‑safety analyses, including non‑compartmental analysis, population PK modeling, and PK‑PD modeling and simulations to support dose selection, exposure‑response and exposure‑safety analyses through various phases of drug development.
• Proficiency with Win Nonlin, Monolix, NONMEM, R or other modeling software.
• Effective skills directed toward driving collaboration, achieving results, influencing, and resolving conflicts across internal and external stakeholders.
• Demonstrated experience responding to regulatory agency questions, preparing clinical pharmacology aspects of regulatory submissions and attending regulatory meetings.
• Highly motivated, decisive, and results‑oriented individual who is proactive, resourceful, and efficient with the flexibility and creativity to excel in and contribute to a rapidly growing drug discovery and development company.

Experience in oncology is preferred, but not an absolute requirement.

This position can be based in either Salt Lake City or New York City. The role is hybrid; employees are expected to spend 50% of their time in the office.

Estimated annual base range: $212,900 to $281,600. Eligible for annual bonus, equity compensation and a comprehensive benefits package.

• We act boldly with integrity.
• We care deeply and engage directly.
• We learn actively and adapt rapidly.
• We move with urgency because patients are waiting.
• We take ownership and accountability.
• We are One Recursion.

These values underpin the employee experience y are the character and personality of the company demonstrated through how we communicate, support one another, spend our time, make decisions and celebrate collectively.

Recursion (NASDAQ: RXRX) is a clinical‑stage Tech Bio company…